Key facts
- Notable investors include Verge Capital Management, ANDHealth, AusBiotech, MTPConnect.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Macuject
- ·The full record, as it builds
Funding rounds
No funding rounds for Macuject are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Macuject
Developer of an AI-powered clinical decision support platform designed to improve treatment precision in retinal care, with a focus on age-related macular degeneration. The company offers seamless workflow integration, real-time capture of physician rationale, and linkage to longitudinal imaging data, enabling eye care providers and pharmaceutical partners to achieve enhanced patient outcomes, operational efficiency, and high-fidelity real-world evidence generation.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2017
- Employees
- 11
- Website
- macuject.com/
- Ownership
- Privately Held (backing)
Macuject doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Macuject shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Macuject in its N-PORT filings yet. We sweep new filings monthly.